Boehringer's Nerandomilast Achieves Milestone in Phase-III FIBRONEER™-IPF Study
Sunday, 15 September 2024, 23:05
Milestone Achievement in IPF Treatment
Boehringer Ingelheim’s nerandomilast has shown promising results, meeting the primary endpoint in the pivotal Phase-III FIBRONEER™-IPF study. This development is crucial in addressing the unmet needs of patients suffering from idiopathic pulmonary fibrosis (IPF). A new drug application (NDA) is anticipated as a result of these findings.
Details of the Study
- The FIBRONEER™-IPF study assessed the efficacy of nerandomilast in patients with IPF.
- This was part of a comprehensive Phase III program, which also includes FIBRONEER™-ILD.
As the deadline for submission approaches, experts in the field are optimistic about the drug's potential impact on the treatment of IPF.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.